nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—ALB—Tacrolimus—atopic dermatitis	0.0656	0.0937	CbGbCtD
Naloxone—CYP2C8—Mometasone—atopic dermatitis	0.0646	0.0923	CbGbCtD
Naloxone—SLCO1A2—Prednisolone—atopic dermatitis	0.0546	0.0779	CbGbCtD
Naloxone—SLCO1A2—Hydrocortisone—atopic dermatitis	0.0517	0.0738	CbGbCtD
Naloxone—SLCO1A2—Prednisone—atopic dermatitis	0.0515	0.0736	CbGbCtD
Naloxone—CYP2C8—Loratadine—atopic dermatitis	0.0371	0.053	CbGbCtD
Naloxone—CYP3A4—Pimecrolimus—atopic dermatitis	0.0346	0.0494	CbGbCtD
Naloxone—ABCB1—Tacrolimus—atopic dermatitis	0.0343	0.049	CbGbCtD
Naloxone—SLCO1A2—Dexamethasone—atopic dermatitis	0.0322	0.0459	CbGbCtD
Naloxone—ALB—Prednisone—atopic dermatitis	0.0266	0.038	CbGbCtD
Naloxone—ABCB1—Loratadine—atopic dermatitis	0.0251	0.0359	CbGbCtD
Naloxone—ABCB1—Methylprednisolone—atopic dermatitis	0.023	0.0328	CbGbCtD
Naloxone—CYP2C8—Hydrocortisone—atopic dermatitis	0.0207	0.0295	CbGbCtD
Naloxone—CYP3A4—Tacrolimus—atopic dermatitis	0.0206	0.0294	CbGbCtD
Naloxone—CYP3A4—Loratadine—atopic dermatitis	0.0151	0.0215	CbGbCtD
Naloxone—ABCB1—Betamethasone—atopic dermatitis	0.0149	0.0213	CbGbCtD
Naloxone—ABCB1—Prednisolone—atopic dermatitis	0.0147	0.021	CbGbCtD
Naloxone—ABCB1—Hydrocortisone—atopic dermatitis	0.014	0.02	CbGbCtD
Naloxone—ABCB1—Prednisone—atopic dermatitis	0.0139	0.0199	CbGbCtD
Naloxone—CYP3A4—Methylprednisolone—atopic dermatitis	0.0138	0.0197	CbGbCtD
Naloxone—CYP2C8—Dexamethasone—atopic dermatitis	0.0128	0.0183	CbGbCtD
Naloxone—CYP3A4—Triamcinolone—atopic dermatitis	0.0104	0.0149	CbGbCtD
Naloxone—CYP3A4—Betamethasone—atopic dermatitis	0.00895	0.0128	CbGbCtD
Naloxone—CYP3A4—Prednisolone—atopic dermatitis	0.00883	0.0126	CbGbCtD
Naloxone—ABCB1—Dexamethasone—atopic dermatitis	0.00869	0.0124	CbGbCtD
Naloxone—CYP3A4—Hydrocortisone—atopic dermatitis	0.00838	0.012	CbGbCtD
Naloxone—CYP3A4—Prednisone—atopic dermatitis	0.00834	0.0119	CbGbCtD
Naloxone—CYP3A4—Dexamethasone—atopic dermatitis	0.00521	0.00744	CbGbCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Desonide—atopic dermatitis	0.00107	0.00746	CcSEcCtD
Naloxone—Coma—Tacrolimus—atopic dermatitis	0.00101	0.00709	CcSEcCtD
Naloxone—Nervous system disorder—Desonide—atopic dermatitis	0.00101	0.00706	CcSEcCtD
Naloxone—Skin disorder—Desonide—atopic dermatitis	0.001	0.00699	CcSEcCtD
Naloxone—Hyperhidrosis—Desonide—atopic dermatitis	0.000997	0.00696	CcSEcCtD
Naloxone—Pulmonary oedema—Tacrolimus—atopic dermatitis	0.000989	0.0069	CcSEcCtD
Naloxone—Flushing—Pimecrolimus—atopic dermatitis	0.000951	0.00665	CcSEcCtD
Naloxone—Chills—Dimenhydrinate—atopic dermatitis	0.000951	0.00664	CcSEcCtD
Naloxone—Chills—Diphenhydramine—atopic dermatitis	0.000951	0.00664	CcSEcCtD
Naloxone—Nasopharyngitis—Fluocinolone Acetonide—atopic dermatitis	0.000949	0.00663	CcSEcCtD
Naloxone—Mediastinal disorder—Pimecrolimus—atopic dermatitis	0.000924	0.00645	CcSEcCtD
Naloxone—Depression—Loratadine—atopic dermatitis	0.000907	0.00633	CcSEcCtD
Naloxone—Nasopharyngitis—Mometasone—atopic dermatitis	0.000906	0.00633	CcSEcCtD
Naloxone—Tension—Dimenhydrinate—atopic dermatitis	0.000906	0.00633	CcSEcCtD
Naloxone—Tension—Diphenhydramine—atopic dermatitis	0.000906	0.00633	CcSEcCtD
Naloxone—Nervousness—Dimenhydrinate—atopic dermatitis	0.000896	0.00626	CcSEcCtD
Naloxone—Nervousness—Diphenhydramine—atopic dermatitis	0.000896	0.00626	CcSEcCtD
Naloxone—Pain—Desonide—atopic dermatitis	0.000882	0.00616	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Fluocinonide—atopic dermatitis	0.000865	0.00604	CcSEcCtD
Naloxone—Tremor—Dimenhydrinate—atopic dermatitis	0.000865	0.00604	CcSEcCtD
Naloxone—Tremor—Diphenhydramine—atopic dermatitis	0.000865	0.00604	CcSEcCtD
Naloxone—Hot flush—Tacrolimus—atopic dermatitis	0.000862	0.00602	CcSEcCtD
Naloxone—Menopausal symptoms—Tacrolimus—atopic dermatitis	0.000854	0.00597	CcSEcCtD
Naloxone—Agitation—Dimenhydrinate—atopic dermatitis	0.000848	0.00592	CcSEcCtD
Naloxone—Agitation—Diphenhydramine—atopic dermatitis	0.000848	0.00592	CcSEcCtD
Naloxone—Nervous system disorder—Fluocinonide—atopic dermatitis	0.000819	0.00572	CcSEcCtD
Naloxone—Skin disorder—Fluocinonide—atopic dermatitis	0.000811	0.00567	CcSEcCtD
Naloxone—Convulsion—Dimenhydrinate—atopic dermatitis	0.0008	0.00559	CcSEcCtD
Naloxone—Convulsion—Diphenhydramine—atopic dermatitis	0.0008	0.00559	CcSEcCtD
Naloxone—Cardiac arrest—Tacrolimus—atopic dermatitis	0.000767	0.00535	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Pimecrolimus—atopic dermatitis	0.000755	0.00527	CcSEcCtD
Naloxone—Tachycardia—Diphenhydramine—atopic dermatitis	0.000735	0.00513	CcSEcCtD
Naloxone—Tachycardia—Dimenhydrinate—atopic dermatitis	0.000735	0.00513	CcSEcCtD
Naloxone—Hyperhidrosis—Dimenhydrinate—atopic dermatitis	0.000728	0.00509	CcSEcCtD
Naloxone—Hyperhidrosis—Diphenhydramine—atopic dermatitis	0.000728	0.00509	CcSEcCtD
Naloxone—Pain—Fluocinonide—atopic dermatitis	0.000714	0.00499	CcSEcCtD
Naloxone—Nervous system disorder—Pimecrolimus—atopic dermatitis	0.000714	0.00499	CcSEcCtD
Naloxone—Skin disorder—Pimecrolimus—atopic dermatitis	0.000707	0.00494	CcSEcCtD
Naloxone—Tension—Loratadine—atopic dermatitis	0.000698	0.00487	CcSEcCtD
Naloxone—Nervousness—Loratadine—atopic dermatitis	0.00069	0.00482	CcSEcCtD
Naloxone—Paraesthesia—Dimenhydrinate—atopic dermatitis	0.000676	0.00472	CcSEcCtD
Naloxone—Paraesthesia—Diphenhydramine—atopic dermatitis	0.000676	0.00472	CcSEcCtD
Naloxone—Mediastinal disorder—Fluocinolone Acetonide—atopic dermatitis	0.000661	0.00462	CcSEcCtD
Naloxone—Paraesthesia—Pimecrolimus—atopic dermatitis	0.000654	0.00457	CcSEcCtD
Naloxone—Agitation—Loratadine—atopic dermatitis	0.000653	0.00456	CcSEcCtD
Naloxone—Dyspnoea—Pimecrolimus—atopic dermatitis	0.000649	0.00454	CcSEcCtD
Naloxone—Mental disorder—Fluocinolone Acetonide—atopic dermatitis	0.000643	0.00449	CcSEcCtD
Naloxone—Mediastinal disorder—Mometasone—atopic dermatitis	0.000632	0.00441	CcSEcCtD
Naloxone—Pulmonary oedema—Prednisolone—atopic dermatitis	0.000631	0.00441	CcSEcCtD
Naloxone—Gastrointestinal disorder—Pimecrolimus—atopic dermatitis	0.000629	0.00439	CcSEcCtD
Naloxone—Pain—Pimecrolimus—atopic dermatitis	0.000623	0.00435	CcSEcCtD
Naloxone—Depression—Tacrolimus—atopic dermatitis	0.000619	0.00433	CcSEcCtD
Naloxone—Pulmonary oedema—Hydrocortisone—atopic dermatitis	0.000617	0.00431	CcSEcCtD
Naloxone—Hypertension—Loratadine—atopic dermatitis	0.000614	0.00429	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Loratadine—atopic dermatitis	0.000601	0.0042	CcSEcCtD
Naloxone—Sweating—Tacrolimus—atopic dermatitis	0.000596	0.00416	CcSEcCtD
Naloxone—Pulmonary oedema—Triamcinolone—atopic dermatitis	0.000581	0.00406	CcSEcCtD
Naloxone—Pulmonary oedema—Methylprednisolone—atopic dermatitis	0.000579	0.00405	CcSEcCtD
Naloxone—Abdominal pain—Pimecrolimus—atopic dermatitis	0.000576	0.00402	CcSEcCtD
Naloxone—Body temperature increased—Pimecrolimus—atopic dermatitis	0.000576	0.00402	CcSEcCtD
Naloxone—Nervous system disorder—Loratadine—atopic dermatitis	0.000569	0.00397	CcSEcCtD
Naloxone—Tachycardia—Loratadine—atopic dermatitis	0.000566	0.00395	CcSEcCtD
Naloxone—Skin disorder—Loratadine—atopic dermatitis	0.000563	0.00394	CcSEcCtD
Naloxone—Hallucination—Tacrolimus—atopic dermatitis	0.000555	0.00388	CcSEcCtD
Naloxone—Asthenia—Diphenhydramine—atopic dermatitis	0.00054	0.00377	CcSEcCtD
Naloxone—Asthenia—Dimenhydrinate—atopic dermatitis	0.00054	0.00377	CcSEcCtD
Naloxone—Pulmonary oedema—Dexamethasone—atopic dermatitis	0.000527	0.00368	CcSEcCtD
Naloxone—Pulmonary oedema—Betamethasone—atopic dermatitis	0.000527	0.00368	CcSEcCtD
Naloxone—Paraesthesia—Loratadine—atopic dermatitis	0.000521	0.00364	CcSEcCtD
Naloxone—Cardiac disorder—Tacrolimus—atopic dermatitis	0.000518	0.00362	CcSEcCtD
Naloxone—Flushing—Tacrolimus—atopic dermatitis	0.000518	0.00362	CcSEcCtD
Naloxone—Diarrhoea—Diphenhydramine—atopic dermatitis	0.000515	0.0036	CcSEcCtD
Naloxone—Diarrhoea—Dimenhydrinate—atopic dermatitis	0.000515	0.0036	CcSEcCtD
Naloxone—Nervous system disorder—Fluocinolone Acetonide—atopic dermatitis	0.000511	0.00357	CcSEcCtD
Naloxone—Angiopathy—Tacrolimus—atopic dermatitis	0.000506	0.00353	CcSEcCtD
Naloxone—Mediastinal disorder—Tacrolimus—atopic dermatitis	0.000503	0.00351	CcSEcCtD
Naloxone—Gastrointestinal disorder—Loratadine—atopic dermatitis	0.000501	0.0035	CcSEcCtD
Naloxone—Chills—Tacrolimus—atopic dermatitis	0.0005	0.0035	CcSEcCtD
Naloxone—Diarrhoea—Pimecrolimus—atopic dermatitis	0.000498	0.00348	CcSEcCtD
Naloxone—Pain—Loratadine—atopic dermatitis	0.000496	0.00346	CcSEcCtD
Naloxone—Cardiac arrest—Prednisolone—atopic dermatitis	0.00049	0.00342	CcSEcCtD
Naloxone—Mental disorder—Tacrolimus—atopic dermatitis	0.000489	0.00341	CcSEcCtD
Naloxone—Irritability—Hydrocortisone—atopic dermatitis	0.00048	0.00335	CcSEcCtD
Naloxone—Vomiting—Diphenhydramine—atopic dermatitis	0.000479	0.00334	CcSEcCtD
Naloxone—Vomiting—Dimenhydrinate—atopic dermatitis	0.000479	0.00334	CcSEcCtD
Naloxone—Cardiac arrest—Hydrocortisone—atopic dermatitis	0.000478	0.00334	CcSEcCtD
Naloxone—Tension—Tacrolimus—atopic dermatitis	0.000476	0.00333	CcSEcCtD
Naloxone—Nervousness—Tacrolimus—atopic dermatitis	0.000472	0.00329	CcSEcCtD
Naloxone—Vomiting—Pimecrolimus—atopic dermatitis	0.000463	0.00323	CcSEcCtD
Naloxone—Pulmonary oedema—Prednisone—atopic dermatitis	0.000459	0.0032	CcSEcCtD
Naloxone—Abdominal pain—Loratadine—atopic dermatitis	0.000459	0.0032	CcSEcCtD
Naloxone—Body temperature increased—Loratadine—atopic dermatitis	0.000459	0.0032	CcSEcCtD
Naloxone—Tremor—Tacrolimus—atopic dermatitis	0.000455	0.00318	CcSEcCtD
Naloxone—Irritability—Methylprednisolone—atopic dermatitis	0.000451	0.00315	CcSEcCtD
Naloxone—Cardiac arrest—Triamcinolone—atopic dermatitis	0.00045	0.00314	CcSEcCtD
Naloxone—Gastrointestinal disorder—Fluocinolone Acetonide—atopic dermatitis	0.00045	0.00314	CcSEcCtD
Naloxone—Hyperkinesia—Prednisone—atopic dermatitis	0.00045	0.00314	CcSEcCtD
Naloxone—Cardiac arrest—Methylprednisolone—atopic dermatitis	0.000449	0.00314	CcSEcCtD
Naloxone—Nausea—Dimenhydrinate—atopic dermatitis	0.000447	0.00312	CcSEcCtD
Naloxone—Nausea—Diphenhydramine—atopic dermatitis	0.000447	0.00312	CcSEcCtD
Naloxone—Paraesthesia—Mometasone—atopic dermatitis	0.000447	0.00312	CcSEcCtD
Naloxone—Agitation—Tacrolimus—atopic dermatitis	0.000446	0.00312	CcSEcCtD
Naloxone—Pain—Fluocinolone Acetonide—atopic dermatitis	0.000446	0.00311	CcSEcCtD
Naloxone—Dyspnoea—Mometasone—atopic dermatitis	0.000444	0.0031	CcSEcCtD
Naloxone—Nausea—Pimecrolimus—atopic dermatitis	0.000433	0.00302	CcSEcCtD
Naloxone—Pain—Mometasone—atopic dermatitis	0.000426	0.00297	CcSEcCtD
Naloxone—Convulsion—Tacrolimus—atopic dermatitis	0.000421	0.00294	CcSEcCtD
Naloxone—Hypertension—Tacrolimus—atopic dermatitis	0.000419	0.00293	CcSEcCtD
Naloxone—Asthenia—Loratadine—atopic dermatitis	0.000416	0.00291	CcSEcCtD
Naloxone—Body temperature increased—Fluocinolone Acetonide—atopic dermatitis	0.000412	0.00288	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Tacrolimus—atopic dermatitis	0.00041	0.00287	CcSEcCtD
Naloxone—Irritability—Betamethasone—atopic dermatitis	0.00041	0.00286	CcSEcCtD
Naloxone—Irritability—Dexamethasone—atopic dermatitis	0.00041	0.00286	CcSEcCtD
Naloxone—Cardiac arrest—Dexamethasone—atopic dermatitis	0.000409	0.00285	CcSEcCtD
Naloxone—Cardiac arrest—Betamethasone—atopic dermatitis	0.000409	0.00285	CcSEcCtD
Naloxone—Diarrhoea—Loratadine—atopic dermatitis	0.000397	0.00277	CcSEcCtD
Naloxone—Body temperature increased—Mometasone—atopic dermatitis	0.000394	0.00275	CcSEcCtD
Naloxone—Abdominal pain—Mometasone—atopic dermatitis	0.000394	0.00275	CcSEcCtD
Naloxone—Nervous system disorder—Tacrolimus—atopic dermatitis	0.000389	0.00271	CcSEcCtD
Naloxone—Tachycardia—Tacrolimus—atopic dermatitis	0.000387	0.0027	CcSEcCtD
Naloxone—Skin disorder—Tacrolimus—atopic dermatitis	0.000385	0.00269	CcSEcCtD
Naloxone—Hyperhidrosis—Tacrolimus—atopic dermatitis	0.000383	0.00268	CcSEcCtD
Naloxone—Vomiting—Loratadine—atopic dermatitis	0.000369	0.00258	CcSEcCtD
Naloxone—Asthenia—Mometasone—atopic dermatitis	0.000357	0.00249	CcSEcCtD
Naloxone—Irritability—Prednisone—atopic dermatitis	0.000357	0.00249	CcSEcCtD
Naloxone—Diarrhoea—Fluocinolone Acetonide—atopic dermatitis	0.000357	0.00249	CcSEcCtD
Naloxone—Cardiac arrest—Prednisone—atopic dermatitis	0.000356	0.00249	CcSEcCtD
Naloxone—Paraesthesia—Tacrolimus—atopic dermatitis	0.000356	0.00249	CcSEcCtD
Naloxone—Dyspnoea—Tacrolimus—atopic dermatitis	0.000353	0.00247	CcSEcCtD
Naloxone—Sweating—Methylprednisolone—atopic dermatitis	0.000349	0.00244	CcSEcCtD
Naloxone—Hallucination—Hydrocortisone—atopic dermatitis	0.000346	0.00242	CcSEcCtD
Naloxone—Nausea—Loratadine—atopic dermatitis	0.000345	0.00241	CcSEcCtD
Naloxone—Gastrointestinal disorder—Tacrolimus—atopic dermatitis	0.000342	0.00239	CcSEcCtD
Naloxone—Diarrhoea—Mometasone—atopic dermatitis	0.000341	0.00238	CcSEcCtD
Naloxone—Pain—Tacrolimus—atopic dermatitis	0.000339	0.00237	CcSEcCtD
Naloxone—Vomiting—Fluocinolone Acetonide—atopic dermatitis	0.000331	0.00232	CcSEcCtD
Naloxone—Hallucination—Methylprednisolone—atopic dermatitis	0.000325	0.00227	CcSEcCtD
Naloxone—Vomiting—Mometasone—atopic dermatitis	0.000317	0.00221	CcSEcCtD
Naloxone—Abdominal pain—Tacrolimus—atopic dermatitis	0.000313	0.00219	CcSEcCtD
Naloxone—Body temperature increased—Tacrolimus—atopic dermatitis	0.000313	0.00219	CcSEcCtD
Naloxone—Nausea—Fluocinolone Acetonide—atopic dermatitis	0.00031	0.00216	CcSEcCtD
Naloxone—Mental disorder—Hydrocortisone—atopic dermatitis	0.000305	0.00213	CcSEcCtD
Naloxone—Cardiac disorder—Methylprednisolone—atopic dermatitis	0.000303	0.00212	CcSEcCtD
Naloxone—Angiopathy—Methylprednisolone—atopic dermatitis	0.000297	0.00207	CcSEcCtD
Naloxone—Hallucination—Betamethasone—atopic dermatitis	0.000296	0.00207	CcSEcCtD
Naloxone—Hallucination—Dexamethasone—atopic dermatitis	0.000296	0.00207	CcSEcCtD
Naloxone—Nausea—Mometasone—atopic dermatitis	0.000296	0.00207	CcSEcCtD
Naloxone—Mediastinal disorder—Methylprednisolone—atopic dermatitis	0.000295	0.00206	CcSEcCtD
Naloxone—Depression—Prednisone—atopic dermatitis	0.000288	0.00201	CcSEcCtD
Naloxone—Mental disorder—Methylprednisolone—atopic dermatitis	0.000286	0.002	CcSEcCtD
Naloxone—Asthenia—Tacrolimus—atopic dermatitis	0.000284	0.00199	CcSEcCtD
Naloxone—Diarrhoea—Tacrolimus—atopic dermatitis	0.000271	0.00189	CcSEcCtD
Naloxone—Angiopathy—Dexamethasone—atopic dermatitis	0.00027	0.00188	CcSEcCtD
Naloxone—Angiopathy—Betamethasone—atopic dermatitis	0.00027	0.00188	CcSEcCtD
Naloxone—Convulsion—Prednisolone—atopic dermatitis	0.000269	0.00188	CcSEcCtD
Naloxone—Hypertension—Prednisolone—atopic dermatitis	0.000268	0.00187	CcSEcCtD
Naloxone—Convulsion—Hydrocortisone—atopic dermatitis	0.000262	0.00183	CcSEcCtD
Naloxone—Hypertension—Hydrocortisone—atopic dermatitis	0.000261	0.00183	CcSEcCtD
Naloxone—Hallucination—Prednisone—atopic dermatitis	0.000258	0.0018	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—atopic dermatitis	0.000256	0.00179	CcSEcCtD
Naloxone—Vomiting—Tacrolimus—atopic dermatitis	0.000252	0.00176	CcSEcCtD
Naloxone—Convulsion—Triamcinolone—atopic dermatitis	0.000247	0.00173	CcSEcCtD
Naloxone—Tachycardia—Prednisolone—atopic dermatitis	0.000247	0.00173	CcSEcCtD
Naloxone—Convulsion—Methylprednisolone—atopic dermatitis	0.000247	0.00172	CcSEcCtD
Naloxone—Hypertension—Triamcinolone—atopic dermatitis	0.000246	0.00172	CcSEcCtD
Naloxone—Hypertension—Methylprednisolone—atopic dermatitis	0.000246	0.00172	CcSEcCtD
Naloxone—Hyperhidrosis—Prednisolone—atopic dermatitis	0.000245	0.00171	CcSEcCtD
Naloxone—Nervous system disorder—Hydrocortisone—atopic dermatitis	0.000242	0.00169	CcSEcCtD
Naloxone—Tachycardia—Hydrocortisone—atopic dermatitis	0.000241	0.00168	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	0.000241	0.00168	CcSEcCtD
Naloxone—Flushing—Prednisone—atopic dermatitis	0.00024	0.00168	CcSEcCtD
Naloxone—Skin disorder—Hydrocortisone—atopic dermatitis	0.00024	0.00168	CcSEcCtD
Naloxone—Hyperhidrosis—Hydrocortisone—atopic dermatitis	0.000239	0.00167	CcSEcCtD
Naloxone—Nausea—Tacrolimus—atopic dermatitis	0.000235	0.00164	CcSEcCtD
Naloxone—Angiopathy—Prednisone—atopic dermatitis	0.000235	0.00164	CcSEcCtD
Naloxone—Nervous system disorder—Methylprednisolone—atopic dermatitis	0.000228	0.00159	CcSEcCtD
Naloxone—Paraesthesia—Prednisolone—atopic dermatitis	0.000227	0.00159	CcSEcCtD
Naloxone—Tachycardia—Triamcinolone—atopic dermatitis	0.000227	0.00159	CcSEcCtD
Naloxone—Mental disorder—Prednisone—atopic dermatitis	0.000227	0.00158	CcSEcCtD
Naloxone—Tachycardia—Methylprednisolone—atopic dermatitis	0.000227	0.00158	CcSEcCtD
Naloxone—Skin disorder—Methylprednisolone—atopic dermatitis	0.000226	0.00158	CcSEcCtD
Naloxone—Hyperhidrosis—Triamcinolone—atopic dermatitis	0.000225	0.00157	CcSEcCtD
Naloxone—Hyperhidrosis—Methylprednisolone—atopic dermatitis	0.000224	0.00157	CcSEcCtD
Naloxone—Convulsion—Dexamethasone—atopic dermatitis	0.000224	0.00157	CcSEcCtD
Naloxone—Convulsion—Betamethasone—atopic dermatitis	0.000224	0.00157	CcSEcCtD
Naloxone—Hypertension—Betamethasone—atopic dermatitis	0.000223	0.00156	CcSEcCtD
Naloxone—Hypertension—Dexamethasone—atopic dermatitis	0.000223	0.00156	CcSEcCtD
Naloxone—Paraesthesia—Hydrocortisone—atopic dermatitis	0.000222	0.00155	CcSEcCtD
Naloxone—Pain—Prednisolone—atopic dermatitis	0.000216	0.00151	CcSEcCtD
Naloxone—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	0.000213	0.00149	CcSEcCtD
Naloxone—Pain—Hydrocortisone—atopic dermatitis	0.000211	0.00148	CcSEcCtD
Naloxone—Paraesthesia—Triamcinolone—atopic dermatitis	0.000209	0.00146	CcSEcCtD
Naloxone—Paraesthesia—Methylprednisolone—atopic dermatitis	0.000209	0.00146	CcSEcCtD
Naloxone—Dyspnoea—Triamcinolone—atopic dermatitis	0.000208	0.00145	CcSEcCtD
Naloxone—Nervous system disorder—Dexamethasone—atopic dermatitis	0.000207	0.00145	CcSEcCtD
Naloxone—Nervous system disorder—Betamethasone—atopic dermatitis	0.000207	0.00145	CcSEcCtD
Naloxone—Agitation—Prednisone—atopic dermatitis	0.000207	0.00145	CcSEcCtD
Naloxone—Tachycardia—Dexamethasone—atopic dermatitis	0.000206	0.00144	CcSEcCtD
Naloxone—Tachycardia—Betamethasone—atopic dermatitis	0.000206	0.00144	CcSEcCtD
Naloxone—Hyperhidrosis—Betamethasone—atopic dermatitis	0.000204	0.00143	CcSEcCtD
Naloxone—Hyperhidrosis—Dexamethasone—atopic dermatitis	0.000204	0.00143	CcSEcCtD
Naloxone—Pain—Triamcinolone—atopic dermatitis	0.000199	0.00139	CcSEcCtD
Naloxone—Abdominal pain—Hydrocortisone—atopic dermatitis	0.000195	0.00136	CcSEcCtD
Naloxone—Body temperature increased—Hydrocortisone—atopic dermatitis	0.000195	0.00136	CcSEcCtD
Naloxone—Convulsion—Prednisone—atopic dermatitis	0.000195	0.00136	CcSEcCtD
Naloxone—Hypertension—Prednisone—atopic dermatitis	0.000195	0.00136	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	0.000191	0.00133	CcSEcCtD
Naloxone—Paraesthesia—Dexamethasone—atopic dermatitis	0.00019	0.00132	CcSEcCtD
Naloxone—Paraesthesia—Betamethasone—atopic dermatitis	0.00019	0.00132	CcSEcCtD
Naloxone—Body temperature increased—Triamcinolone—atopic dermatitis	0.000184	0.00129	CcSEcCtD
Naloxone—Abdominal pain—Methylprednisolone—atopic dermatitis	0.000184	0.00128	CcSEcCtD
Naloxone—Gastrointestinal disorder—Betamethasone—atopic dermatitis	0.000182	0.00127	CcSEcCtD
Naloxone—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	0.000182	0.00127	CcSEcCtD
Naloxone—Pain—Dexamethasone—atopic dermatitis	0.000181	0.00126	CcSEcCtD
Naloxone—Pain—Betamethasone—atopic dermatitis	0.000181	0.00126	CcSEcCtD
Naloxone—Nervous system disorder—Prednisone—atopic dermatitis	0.00018	0.00126	CcSEcCtD
Naloxone—Tachycardia—Prednisone—atopic dermatitis	0.000179	0.00125	CcSEcCtD
Naloxone—Skin disorder—Prednisone—atopic dermatitis	0.000179	0.00125	CcSEcCtD
Naloxone—Hyperhidrosis—Prednisone—atopic dermatitis	0.000178	0.00124	CcSEcCtD
Naloxone—Asthenia—Hydrocortisone—atopic dermatitis	0.000177	0.00124	CcSEcCtD
Naloxone—Diarrhoea—Hydrocortisone—atopic dermatitis	0.000169	0.00118	CcSEcCtD
Naloxone—Asthenia—Triamcinolone—atopic dermatitis	0.000167	0.00117	CcSEcCtD
Naloxone—Abdominal pain—Betamethasone—atopic dermatitis	0.000167	0.00117	CcSEcCtD
Naloxone—Abdominal pain—Dexamethasone—atopic dermatitis	0.000167	0.00117	CcSEcCtD
Naloxone—Body temperature increased—Dexamethasone—atopic dermatitis	0.000167	0.00117	CcSEcCtD
Naloxone—Body temperature increased—Betamethasone—atopic dermatitis	0.000167	0.00117	CcSEcCtD
Naloxone—Asthenia—Methylprednisolone—atopic dermatitis	0.000167	0.00116	CcSEcCtD
Naloxone—Paraesthesia—Prednisone—atopic dermatitis	0.000165	0.00115	CcSEcCtD
Naloxone—Diarrhoea—Methylprednisolone—atopic dermatitis	0.000159	0.00111	CcSEcCtD
Naloxone—Vomiting—Hydrocortisone—atopic dermatitis	0.000157	0.0011	CcSEcCtD
Naloxone—Asthenia—Dexamethasone—atopic dermatitis	0.000152	0.00106	CcSEcCtD
Naloxone—Asthenia—Betamethasone—atopic dermatitis	0.000152	0.00106	CcSEcCtD
Naloxone—Nausea—Prednisolone—atopic dermatitis	0.00015	0.00105	CcSEcCtD
Naloxone—Vomiting—Triamcinolone—atopic dermatitis	0.000148	0.00103	CcSEcCtD
Naloxone—Vomiting—Methylprednisolone—atopic dermatitis	0.000148	0.00103	CcSEcCtD
Naloxone—Nausea—Hydrocortisone—atopic dermatitis	0.000147	0.00103	CcSEcCtD
Naloxone—Abdominal pain—Prednisone—atopic dermatitis	0.000145	0.00102	CcSEcCtD
Naloxone—Body temperature increased—Prednisone—atopic dermatitis	0.000145	0.00102	CcSEcCtD
Naloxone—Diarrhoea—Betamethasone—atopic dermatitis	0.000144	0.00101	CcSEcCtD
Naloxone—Diarrhoea—Dexamethasone—atopic dermatitis	0.000144	0.00101	CcSEcCtD
Naloxone—Nausea—Triamcinolone—atopic dermatitis	0.000138	0.000966	CcSEcCtD
Naloxone—Nausea—Methylprednisolone—atopic dermatitis	0.000138	0.000963	CcSEcCtD
Naloxone—Vomiting—Dexamethasone—atopic dermatitis	0.000134	0.000938	CcSEcCtD
Naloxone—Vomiting—Betamethasone—atopic dermatitis	0.000134	0.000938	CcSEcCtD
Naloxone—Asthenia—Prednisone—atopic dermatitis	0.000132	0.000922	CcSEcCtD
Naloxone—Diarrhoea—Prednisone—atopic dermatitis	0.000126	0.000879	CcSEcCtD
Naloxone—Nausea—Betamethasone—atopic dermatitis	0.000125	0.000876	CcSEcCtD
Naloxone—Nausea—Dexamethasone—atopic dermatitis	0.000125	0.000876	CcSEcCtD
Naloxone—Vomiting—Prednisone—atopic dermatitis	0.000117	0.000817	CcSEcCtD
Naloxone—Nausea—Prednisone—atopic dermatitis	0.000109	0.000763	CcSEcCtD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	5.93e-05	0.000379	CbGpPWpGaD
Naloxone—CREB1—Myometrial Relaxation and Contraction Pathways—IL6—atopic dermatitis	5.93e-05	0.000379	CbGpPWpGaD
Naloxone—TLR4—Immune System—IL1B—atopic dermatitis	5.9e-05	0.000378	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—IL6—atopic dermatitis	5.9e-05	0.000377	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCL22—atopic dermatitis	5.9e-05	0.000377	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL5—atopic dermatitis	5.88e-05	0.000376	CbGpPWpGaD
Naloxone—TLR4—Immune System—IL2—atopic dermatitis	5.88e-05	0.000376	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL5—atopic dermatitis	5.86e-05	0.000375	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CCR3—atopic dermatitis	5.77e-05	0.000369	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—TNF—atopic dermatitis	5.75e-05	0.000368	CbGpPWpGaD
Naloxone—CREB1—Downstream signal transduction—IL6—atopic dermatitis	5.75e-05	0.000368	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR—IL6—atopic dermatitis	5.72e-05	0.000366	CbGpPWpGaD
Naloxone—ALB—Vitamin B12 Metabolism—IL6—atopic dermatitis	5.71e-05	0.000365	CbGpPWpGaD
Naloxone—CREB1—Signaling by ERBB2—IL6—atopic dermatitis	5.69e-05	0.000364	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—MAPK8—atopic dermatitis	5.69e-05	0.000364	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KIF3A—atopic dermatitis	5.69e-05	0.000364	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KIF3A—atopic dermatitis	5.67e-05	0.000363	CbGpPWpGaD
Naloxone—CREB1—Immune System—CASP1—atopic dermatitis	5.67e-05	0.000363	CbGpPWpGaD
Naloxone—CREB1—DAP12 signaling—IL6—atopic dermatitis	5.67e-05	0.000363	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—IL5—atopic dermatitis	5.66e-05	0.000362	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FCER2—atopic dermatitis	5.62e-05	0.00036	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—CCR5—atopic dermatitis	5.6e-05	0.000358	CbGpPWpGaD
Naloxone—OPRM1—G alpha (i) signalling events—CXCL8—atopic dermatitis	5.59e-05	0.000358	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCL17—atopic dermatitis	5.58e-05	0.000357	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—TAC1—atopic dermatitis	5.53e-05	0.000354	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—NPS—atopic dermatitis	5.53e-05	0.000354	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—CXCL10—atopic dermatitis	5.5e-05	0.000352	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CXCR3—atopic dermatitis	5.42e-05	0.000347	CbGpPWpGaD
Naloxone—TLR4—Immune System—MAPK8—atopic dermatitis	5.41e-05	0.000346	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL5—atopic dermatitis	5.37e-05	0.000344	CbGpPWpGaD
Naloxone—ALB—Hemostasis—SELE—atopic dermatitis	5.35e-05	0.000342	CbGpPWpGaD
Naloxone—CREB1—DAP12 interactions—IL6—atopic dermatitis	5.33e-05	0.000341	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR in disease—IL6—atopic dermatitis	5.33e-05	0.000341	CbGpPWpGaD
Naloxone—CREB1—Fc epsilon receptor (FCERI) signaling—IL6—atopic dermatitis	5.33e-05	0.000341	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR—IL6—atopic dermatitis	5.28e-05	0.000338	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	5.26e-05	0.000336	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCL27—atopic dermatitis	5.25e-05	0.000336	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CCR3—atopic dermatitis	5.24e-05	0.000335	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR in Cancer—IL6—atopic dermatitis	5.24e-05	0.000335	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL22—atopic dermatitis	5.23e-05	0.000334	CbGpPWpGaD
Naloxone—CREB1—Signaling by PDGF—IL6—atopic dermatitis	5.21e-05	0.000334	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—NFKBIA—atopic dermatitis	5.17e-05	0.000331	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	5.15e-05	0.000329	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—TAC1—atopic dermatitis	5.15e-05	0.000329	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—NPS—atopic dermatitis	5.15e-05	0.000329	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCL11—atopic dermatitis	5.14e-05	0.000329	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CMA1—atopic dermatitis	5.14e-05	0.000329	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL5—atopic dermatitis	5.14e-05	0.000329	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CMA1—atopic dermatitis	5.13e-05	0.000328	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCL11—atopic dermatitis	5.13e-05	0.000328	CbGpPWpGaD
Naloxone—CREB1—Immune System—TLR2—atopic dermatitis	5.13e-05	0.000328	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CXCR3—atopic dermatitis	5.05e-05	0.000323	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CXCL10—atopic dermatitis	5.01e-05	0.000321	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CXCL10—atopic dermatitis	5e-05	0.00032	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KIF3A—atopic dermatitis	4.97e-05	0.000318	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—NFKBIA—atopic dermatitis	4.97e-05	0.000318	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—STAT6—atopic dermatitis	4.83e-05	0.000309	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CXCL10—atopic dermatitis	4.83e-05	0.000309	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—STAT6—atopic dermatitis	4.82e-05	0.000308	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD79A—atopic dermatitis	4.82e-05	0.000308	CbGpPWpGaD
Naloxone—CREB1—Circadian rythm related genes—IL6—atopic dermatitis	4.82e-05	0.000308	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	4.79e-05	0.000306	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—IL5—atopic dermatitis	4.78e-05	0.000306	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—CCL5—atopic dermatitis	4.74e-05	0.000303	CbGpPWpGaD
Naloxone—CREB1—NGF signalling via TRKA from the plasma membrane—IL6—atopic dermatitis	4.72e-05	0.000302	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCL17—atopic dermatitis	4.71e-05	0.000301	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—TAC1—atopic dermatitis	4.67e-05	0.000299	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—NPS—atopic dermatitis	4.67e-05	0.000299	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—CASP8—atopic dermatitis	4.66e-05	0.000298	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL27—atopic dermatitis	4.66e-05	0.000298	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—IL6—atopic dermatitis	4.64e-05	0.000297	CbGpPWpGaD
Naloxone—ESR1—Generic Transcription Pathway—PPARA—atopic dermatitis	4.61e-05	0.000295	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	4.59e-05	0.000294	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CXCR3—atopic dermatitis	4.58e-05	0.000293	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—TNF—atopic dermatitis	4.57e-05	0.000292	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—CXCL8—atopic dermatitis	4.57e-05	0.000292	CbGpPWpGaD
Naloxone—CREB1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atopic dermatitis	4.56e-05	0.000292	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—PPARA—atopic dermatitis	4.55e-05	0.000291	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CMA1—atopic dermatitis	4.49e-05	0.000288	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCL11—atopic dermatitis	4.49e-05	0.000288	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	4.44e-05	0.000284	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CXCL10—atopic dermatitis	4.38e-05	0.00028	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—TNF—atopic dermatitis	4.37e-05	0.000279	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL5—atopic dermatitis	4.34e-05	0.000278	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	4.34e-05	0.000278	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CCL5—atopic dermatitis	4.32e-05	0.000276	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CCL5—atopic dermatitis	4.3e-05	0.000275	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—CCR5—atopic dermatitis	4.27e-05	0.000273	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—STAT6—atopic dermatitis	4.23e-05	0.00027	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KIF3A—atopic dermatitis	4.2e-05	0.000269	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCR3—atopic dermatitis	4.19e-05	0.000268	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL17—atopic dermatitis	4.18e-05	0.000267	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCR3—atopic dermatitis	4.18e-05	0.000267	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CCL5—atopic dermatitis	4.15e-05	0.000266	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CXCL10—atopic dermatitis	4.08e-05	0.000261	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	4.07e-05	0.00026	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IL5—atopic dermatitis	4.05e-05	0.000259	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	4.02e-05	0.000257	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—CXCL8—atopic dermatitis	4e-05	0.000256	CbGpPWpGaD
Naloxone—ESR1—Signaling by ERBB4—IL6—atopic dermatitis	3.94e-05	0.000252	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL18—atopic dermatitis	3.94e-05	0.000252	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	3.91e-05	0.00025	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CCR5—atopic dermatitis	3.89e-05	0.000249	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD8A—atopic dermatitis	3.88e-05	0.000248	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CCR5—atopic dermatitis	3.88e-05	0.000248	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—CD4—atopic dermatitis	3.83e-05	0.000245	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCL11—atopic dermatitis	3.8e-05	0.000243	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CMA1—atopic dermatitis	3.8e-05	0.000243	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CCL5—atopic dermatitis	3.77e-05	0.000241	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CCR5—atopic dermatitis	3.74e-05	0.000239	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NPS—atopic dermatitis	3.74e-05	0.000239	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TAC1—atopic dermatitis	3.74e-05	0.000239	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TAC1—atopic dermatitis	3.72e-05	0.000238	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NPS—atopic dermatitis	3.72e-05	0.000238	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KIF3A—atopic dermatitis	3.72e-05	0.000238	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CXCL10—atopic dermatitis	3.7e-05	0.000237	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—IL6—atopic dermatitis	3.69e-05	0.000236	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD4—atopic dermatitis	3.68e-05	0.000235	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCR3—atopic dermatitis	3.66e-05	0.000234	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCR3—atopic dermatitis	3.66e-05	0.000234	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCR3—atopic dermatitis	3.65e-05	0.000234	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—IL6—atopic dermatitis	3.63e-05	0.000232	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—STAT6—atopic dermatitis	3.57e-05	0.000228	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CCL5—atopic dermatitis	3.51e-05	0.000225	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL5—atopic dermatitis	3.47e-05	0.000222	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL5—atopic dermatitis	3.46e-05	0.000221	CbGpPWpGaD
Naloxone—TLR4—Immune System—IL6—atopic dermatitis	3.46e-05	0.000221	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CCR5—atopic dermatitis	3.4e-05	0.000217	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—CXCL8—atopic dermatitis	3.38e-05	0.000216	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CMA1—atopic dermatitis	3.37e-05	0.000215	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL11—atopic dermatitis	3.37e-05	0.000215	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—IL6—atopic dermatitis	3.29e-05	0.00021	CbGpPWpGaD
Naloxone—CREB1—Disease—CCR5—atopic dermatitis	3.28e-05	0.00021	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NPS—atopic dermatitis	3.27e-05	0.000209	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TAC1—atopic dermatitis	3.27e-05	0.000209	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—MAPK8—atopic dermatitis	3.24e-05	0.000208	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GLB1—atopic dermatitis	3.23e-05	0.000206	CbGpPWpGaD
Naloxone—ALB—Metabolism—GLB1—atopic dermatitis	3.21e-05	0.000205	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCR3—atopic dermatitis	3.2e-05	0.000205	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CCL5—atopic dermatitis	3.19e-05	0.000204	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—STAT6—atopic dermatitis	3.17e-05	0.000203	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CCR5—atopic dermatitis	3.16e-05	0.000202	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCR3—atopic dermatitis	3.1e-05	0.000198	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ADSL—atopic dermatitis	3.09e-05	0.000198	CbGpPWpGaD
Naloxone—ALB—Metabolism—ADSL—atopic dermatitis	3.08e-05	0.000197	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL5—atopic dermatitis	3.04e-05	0.000194	CbGpPWpGaD
Naloxone—CREB1—Immune System—NFKBIA—atopic dermatitis	3.01e-05	0.000193	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—IL2—atopic dermatitis	3e-05	0.000192	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCL10—atopic dermatitis	2.96e-05	0.000189	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCL10—atopic dermatitis	2.95e-05	0.000189	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—TNF—atopic dermatitis	2.91e-05	0.000186	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CCR5—atopic dermatitis	2.87e-05	0.000184	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GLB1—atopic dermatitis	2.81e-05	0.00018	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TAC1—atopic dermatitis	2.76e-05	0.000177	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NPS—atopic dermatitis	2.76e-05	0.000177	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCR3—atopic dermatitis	2.75e-05	0.000176	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	2.72e-05	0.000174	CbGpPWpGaD
Naloxone—CREB1—Immune System—CASP8—atopic dermatitis	2.72e-05	0.000174	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCR3—atopic dermatitis	2.71e-05	0.000173	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ADSL—atopic dermatitis	2.7e-05	0.000172	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCL10—atopic dermatitis	2.59e-05	0.000166	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—CXCL8—atopic dermatitis	2.58e-05	0.000165	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL5—atopic dermatitis	2.57e-05	0.000164	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCL5—atopic dermatitis	2.55e-05	0.000163	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCL5—atopic dermatitis	2.54e-05	0.000163	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—IL2—atopic dermatitis	2.47e-05	0.000158	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TAC1—atopic dermatitis	2.45e-05	0.000157	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NPS—atopic dermatitis	2.45e-05	0.000157	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCR3—atopic dermatitis	2.4e-05	0.000154	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NGF—atopic dermatitis	2.36e-05	0.000151	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NGF—atopic dermatitis	2.35e-05	0.000151	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	2.35e-05	0.00015	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CXCL8—atopic dermatitis	2.35e-05	0.00015	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—IL6—atopic dermatitis	2.35e-05	0.00015	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CXCL8—atopic dermatitis	2.34e-05	0.00015	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	2.34e-05	0.00015	CbGpPWpGaD
Naloxone—CREB1—Immune System—IFNG—atopic dermatitis	2.31e-05	0.000148	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCR5—atopic dermatitis	2.3e-05	0.000147	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCR5—atopic dermatitis	2.29e-05	0.000146	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL5—atopic dermatitis	2.28e-05	0.000146	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CXCL8—atopic dermatitis	2.26e-05	0.000145	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL2—atopic dermatitis	2.25e-05	0.000144	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL2—atopic dermatitis	2.24e-05	0.000143	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD4—atopic dermatitis	2.23e-05	0.000143	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCL5—atopic dermatitis	2.23e-05	0.000143	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—PPARA—atopic dermatitis	2.22e-05	0.000142	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—PPARA—atopic dermatitis	2.22e-05	0.000142	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCL10—atopic dermatitis	2.19e-05	0.00014	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—IL2—atopic dermatitis	2.16e-05	0.000138	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	2.15e-05	0.000138	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PPARA—atopic dermatitis	2.13e-05	0.000136	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—IL6—atopic dermatitis	2.07e-05	0.000133	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NGF—atopic dermatitis	2.06e-05	0.000132	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL1B—atopic dermatitis	2.06e-05	0.000132	CbGpPWpGaD
Naloxone—CREB1—Disease—CD4—atopic dermatitis	2.06e-05	0.000132	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CXCL8—atopic dermatitis	2.05e-05	0.000131	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL2—atopic dermatitis	2.05e-05	0.000131	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCR5—atopic dermatitis	2.01e-05	0.000128	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL2—atopic dermatitis	1.96e-05	0.000126	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	1.95e-05	0.000125	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NFKBIA—atopic dermatitis	1.95e-05	0.000125	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NFKBIA—atopic dermatitis	1.94e-05	0.000124	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL10—atopic dermatitis	1.94e-05	0.000124	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CXCL8—atopic dermatitis	1.91e-05	0.000122	CbGpPWpGaD
Naloxone—CREB1—Immune System—MAPK8—atopic dermatitis	1.89e-05	0.000121	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCL5—atopic dermatitis	1.88e-05	0.00012	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—IL2—atopic dermatitis	1.83e-05	0.000117	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NGF—atopic dermatitis	1.74e-05	0.000112	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CXCL8—atopic dermatitis	1.74e-05	0.000111	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GLB1—atopic dermatitis	1.73e-05	0.000111	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NFKBIA—atopic dermatitis	1.7e-05	0.000109	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCR5—atopic dermatitis	1.7e-05	0.000109	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL5—atopic dermatitis	1.67e-05	0.000107	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ADSL—atopic dermatitis	1.66e-05	0.000106	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL2—atopic dermatitis	1.66e-05	0.000106	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IL2—atopic dermatitis	1.55e-05	9.9e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NGF—atopic dermatitis	1.55e-05	9.89e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCR5—atopic dermatitis	1.5e-05	9.62e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NFKBIA—atopic dermatitis	1.44e-05	9.2e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCL8—atopic dermatitis	1.39e-05	8.88e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCL8—atopic dermatitis	1.38e-05	8.86e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL2—atopic dermatitis	1.33e-05	8.49e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL2—atopic dermatitis	1.32e-05	8.46e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL6—atopic dermatitis	1.32e-05	8.45e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL6—atopic dermatitis	1.32e-05	8.42e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NFKBIA—atopic dermatitis	1.28e-05	8.16e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MAPK8—atopic dermatitis	1.22e-05	7.81e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MAPK8—atopic dermatitis	1.22e-05	7.79e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCL8—atopic dermatitis	1.21e-05	7.76e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL6—atopic dermatitis	1.21e-05	7.72e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL2—atopic dermatitis	1.16e-05	7.42e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL6—atopic dermatitis	1.15e-05	7.38e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—IL6—atopic dermatitis	1.11e-05	7.13e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MAPK8—atopic dermatitis	1.07e-05	6.83e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PPARA—atopic dermatitis	1.05e-05	6.7e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PPARA—atopic dermatitis	1.04e-05	6.66e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCL8—atopic dermatitis	1.03e-05	6.56e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL2—atopic dermatitis	9.8e-06	6.27e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL6—atopic dermatitis	9.75e-06	6.24e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PPARA—atopic dermatitis	9.13e-06	5.84e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL8—atopic dermatitis	9.1e-06	5.82e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAPK8—atopic dermatitis	9.02e-06	5.77e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL2—atopic dermatitis	8.69e-06	5.56e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAPK8—atopic dermatitis	8e-06	5.12e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL6—atopic dermatitis	7.8e-06	4.99e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL6—atopic dermatitis	7.78e-06	4.97e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL6—atopic dermatitis	6.82e-06	4.36e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6—atopic dermatitis	5.76e-06	3.69e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PPARA—atopic dermatitis	5.62e-06	3.6e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6—atopic dermatitis	5.11e-06	3.27e-05	CbGpPWpGaD
